Search Within

Ellen Marlese Basu

  1. "GSK Faculty"
Formats
  1. Meeting Abstract (35)
  2. Journal Article (29)
Groups
  1. Center for Molecular Imaging and Biotechnology (CMIB) (64)
  2. GSK Faculty (64)
  3. Neuroblastoma Service (64)
  4. Pediatrics, Department of (64)
  5. Tow Center for Developmental Oncology (TCDO) (63)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (62)

More Groups

People
  1. Shakeel Modak (63)
  2. Brian Kushner (61)
  3. Nai-Kong Cheung (61)
  4. Stephen Roberts (56)
  5. Kim Kramer (34)
  6. Suzanne Wolden (20)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (8)
  4. 2022 (3)
  5. 2021 (5)
  6. 2020 (5)

More Years

Publications
  1. Pediatric Blood and Cancer (22)
  2. Journal of Clinical Oncology (10)
  3. International Journal of Radiation Oncology, Biology, Physics (5)
  4. Cancer (4)
  5. International Journal of Cancer (4)
  6. Neuro-Oncology (3)

More Publications

Publishers
  1. Wiley Periodicals, Inc (22)
  2. American Society of Clinical Oncology (10)
  3. Elsevier Inc. (5)
  4. John Wiley & Sons (4)
  5. Wiley Blackwell (4)
  6. American Association for Cancer Research (3)

More Publishers

Results (64)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression
    Journal Article

    Cheung, I. Y.; Cheung, N. K. V.; Modak, S.; Mauguen, A.; Feng, Y.; Basu, E.; Roberts, S. S.; Ragupathi, G.; Kushner, B. H.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Survival impact of anti-GD2 antibody response - A phase II ganglioside vaccine trial in relapsed neuroblastoma
    Meeting Abstract

    Cheung, I. Y.; Cheung, N. K. V.; Modak, S.; Mauguen, A.; Basu, E.; Roberts, S. S.; Ragupathi, G.; Kushner, B. H.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for Resistant Osteomedullary Neuroblastoma: Major Responses and Outpatient Treatment in a Phase II Trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Favorable toxicity profile of bivalent GD2/GD3 neuroblastoma vaccine
    Meeting Abstract

    Modak, S.; Cheung, N. K.; Basu, E.; Roberts, S.; Kushner, B.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma
    Journal Article

    Luo, L. Y.; Kramer, K.; Cheung, N. K. V.; Kushner, B. H.; Modak, S.; Basu, E. M.; Roberts, S. S.; Wolden, S. L.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Extracellular vesicle and particle biomarkers define multiple human cancers
    Journal Article

    Hoshino, A.; Kim, H. S.; Bojmar, L.; Gyan, K. E.; Cioffi, M.; Hernandez, J.; Zambirinis, C. P.; Rodrigues, G.; Molina, H.; Heissel, S.; more...
    Cell (2020)

    Fulltext@MSK | Save
  • High-dose naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for high-risk neuroblastoma: Efficacy against histologically-evident primary refractory metastases in bone marrow
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) PLUS stepped-up dosing of granulocyte-macrophage colony-stimulating factor for neuroblastoma: Outpatient treament low immunogenicity, and major responses in a phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for relapsed neuroblastoma resistant to salvage therapy: A phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for consolidating >= 2nd complete remission of high-risk neuroblastoma
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save